Serum urate levels were studied in 18 patients with primary hyperparathyroidism (pHPT) and in 36 controls (group 2) matched for age, sex, nationality and blood pressure. These two groups were compared with general surgical inpatients (group 3). The prevalence of hyperuricemia was markedly higher in the pHPT patient group (especially for men) than in the other two groups [44,17 and 9%, respectively; p < 0.05 and < 0.001]. The prevalence of hypertension was markedly higher in the pHPT patient group (66.7%) than in the surgical inpatients [15%; p < 0.0001]. Five of the 9 male patients had both hypertension and hyperuricemia, the pathogenesis of which may be related to the action of hypercalcemia on renal functions. As the prevalence of hypertension and hyperuricemia were markedly higher than previously noted, it is suggested that more attention should be paid to blood pressure, serum urate and renal function in patients with primary hyperparathyroidism, in order to improve diagnosis and therapy.

Keywords:
Hyperparathyroidism, Hypertension, Uric acid
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.